Platelet to lymphocyte ratio plays an important role in prostate cancer’s diagnosis and prognosis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 7, 2015, Pages 11746-11751

  Li, Feng ^a   Hu, Haibo ^b   Gu, Shuo ^c   Chen, Xin ^c   Sun, Qing ^c  

^a The First People's Hospital of Yancheng   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Clinical significance; Mortality; Platelet to lymphocyte ratio; Prognosis; Prostate cancer

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; COMA; COMPARATIVE STUDY; CONTROLLED STUDY; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PLATELET LYMPHOCYTE RATIO; PROSTATE CANCER; PROSTATE HYPERTROPHY; SURVIVAL RATE; THROMBOCYTE COUNT;

EID: 84940676445     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL and Scher HI. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605.
2. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ and Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
3. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC and Trock BJ. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008; 179: 156-161; discussion 161-152.
4. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
5. Srivastava A, Goldberger H, Afzal Z, Suy S, Collins SP and Kumar D. Detection of circulatory microRNAs in prostate cancer. Methods Mol Biol 2015; 1238: 523-538.
6. Katz B, Reis ST, Viana NI, Morais DR, Moura CM, Dip N, Silva IA, Iscaife A, Srougi M and Leite KR. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS One 2014; 9: e113700.
7. Thakur V, Talwar M and Singh PP. Low free to total PSA ratio is not a good discriminator of chronic prostatitis and prostate cancer: An Indian experience. Indian J Cancer 2014; 51: 335-337.
8. Moradi Sardareh H, Goodarzi MT, Yadegar-Azari R, Poorolajal J, Mousavi-Bahar SH and Saidijam M. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals. Urol J 2014; 11: 1952-1958.
9. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N and Clarke SJ. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16: 5805-5813.
10. Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T and Tachibana M. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 2012; 79: 1085-1091.
11. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T and Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 2012; 187: 411-417.
12. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR and Michaelson MD. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2014; 12: 317-324.
13. Turkmen K, Erdur FM, Ozcicek F, Ozcicek A, Akbas EM, Ozbicer A, Demirtas L, Turk S and Tonbul HZ. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int 2013; 17: 391-396.
14. Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D and Mudan S. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol 2014; 31: 239.
15. Niu WB, Gui SL, Lin YL, Fu XL, Ma JG and Li WP. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer. Med Sci Monit 2014; 20: 2584-2589.
16. Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M, Borgmann H, Huesch T, Gust KM, Reiter M, Schilling D, Bartsch G, Haferkamp A and Blaheta RA. CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study. Cancer Res Treat 2015; 47: 306-12.
17. Mohammad AA, Rahbar A, Lui WO, Davoudi B, Catrina A, Stragliotto G, Mellbin L, Hamsten A, Ryden L, Yaiw KC and Soderberg-Naucler C. Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls. PLoS One 2014; 9: e113740.
18. Kelly BD, Miller N, Healy NA, Walsh K and Kerin MJ. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int 2013; 111: 17-21.
19. Li WX and Wu H. Screening for serum markers with protein fingerprint technique in patients with prostate cancer. Zhejiang Med J 2012; 37: 512-514.
20. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocana A, Tannock IF and Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1204-1212.